CoChat

Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives

Open access
Bellis, Alessandro, Mauro, Ciro, Barbato, Emanuele, Ceriello, Antonio, Cittadini, Antonio, Morisco, Carmine · 2021 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 209 of the 216 references it cites were found in a registry or an index.

Abstract

Stress-induced hyperglycaemia (SIH) at hospital admission for acute coronary syndrome is associated with poor outcome, especially in patients without known diabetes. Nevertheless, insulin treatment in these subjects was not correlated with the reduction of mortality. This is likely due to the fact that SIH in the context of an acute coronary syndrome, compared to that in known diabetes, represents an epiphenomenon of other pathological conditions, such as adrenergic and renin-angiotensin system over-activity, hyperglucagonaemia, increase of circulating free fatty acids and pancreatic beta-cell dysfunction, which are not completely reversed by insulin therapy and so worsen the prognosis. Thus, SIH may be considered not only as a biomarker of organ damage, but also as an indicator of a more complex therapeutic strategy in these subjects. The aim of this review is to analyse the molecular mechanisms by which SIH may favour a worse prognosis in non-diabetic patients with acute coronary syndrome and identify new therapeutic strategies, in addition to insulin therapy, for a more appropriate treatment and improved outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22020775

Cites

209 of 209 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanisms of stress-induced hyperglycaemia (SIH) during acute coronary syndrome (ACS) and complementary effects of each pharmacological class. ACS determines SIH by decreasing insulin release through pancreatic beta-cells dysfunction, and by inducing insulin resistance (IR) through overactivation of sympathetic nervous and renin-angiotensin systems. The insulin decrease and adrenergic overdrive provoke hyperglucagonaemia and increase of free fatty acids (FFAs) plasmatic levels, thereby leading to hyperglycaemia. Contemporarily, renin–angiotensin–aldosterone system hyper-stimulation induces IR through the activation of phosphotyrosine phosphatases (PTPases) and reactive oxygen species (ROS) formation. Selective α1/β1-blockers, such as nebivolol, antagonize adrenergic overdrive and have vasodilatory properties that are mediated by stimulation of nitric oxide (NO) release from endothelial cells. ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) inhibit PTPases activity and ROS formation, thereby reducing IR. The n3-polyunsaturated fatty acids (n3-PUFAs) improve cholesterol levels and insulin sensitivity compared to diets high in saturated fats. Dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve pancreatic beta-cells function and reduce glucagon release by alfa-cells, thereby lowering HbA1c levels. Finally, sodium-glucose co-transporters 2 inhibitors (SGLT-2Is) have cardiovascular benefits mostly unrelated to the extent of glucose lowering. They could involve effects on haemodynamic parameters, such as reduced plasma volume, and direct effects on cardiac metabolism and function, such as myocardial fibrosis, cardiac apoptosis and infarct size enlargement. Red lines indicate activation pathways; black lines indicate inhibition pathways; ↑indicates an increase; ↓indicates a decrease.
Figure 1 Mechanisms of stress-induced hyperglycaemia (SIH) during acute coronary syndrome (ACS) and complementary effects of each pharmacological class. ACS determines SIH by decreasing insulin release through pancreatic beta-cells dysfunction, and by inducing insulin resistance (IR) through overactivation of sympathetic nervous and renin-angiotensin systems. The insulin decrease and adrenergic overdrive provoke hyperglucagonaemia and increase of free fatty acids (FFAs) plasmatic levels, thereby leading to hyperglycaemia. Contemporarily, renin–angiotensin–aldosterone system hyper-stimulation induces IR through the activation of phosphotyrosine phosphatases (PTPases) and reactive oxygen species (ROS) formation. Selective α1/β1-blockers, such as nebivolol, antagonize adrenergic overdrive and have vasodilatory properties that are mediated by stimulation of nitric oxide (NO) release from endothelial cells. ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) inhibit PTPases activity and ROS formation, thereby reducing IR. The n3-polyunsaturated fatty acids (n3-PUFAs) improve cholesterol levels and insulin sensitivity compared to diets high in saturated fats. Dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve pancreatic beta-cells function and reduce glucagon release by alfa-cells, thereby lowering HbA1c levels. Finally, sodium-glucose co-transporters 2 inhibitors (SGLT-2Is) have cardiovascular benefits mostly unrelated to the extent of glucose lowering. They could involve effects on haemodynamic parameters, such as reduced plasma volume, and direct effects on cardiac metabolism and function, such as myocardial fibrosis, cardiac apoptosis and infarct size enlargement. Red lines indicate activation pathways; black lines indicate inhibition pathways; ↑indicates an increase; ↓indicates a decrease.CC BY · PubMed Central
Figure 2 Proposal for a multitargeted therapeutic strategy to improve the prognosis in non-diabetic patients with stress-induced hyperglycaemia (SIH) at admission for acute coronary syndrome (ACS). Pharmacological therapy for SIH in non-diabetic ACS patient should start with administration of α1/β1-blockers, ACE inhibitors (ACEi) or angiotensin receptor blockers (ARBs) and n3-polyunsaturated fatty acids (n3-PUFAs) in addition to insulin. If this strategy reaches an efficient glycaemic control (GC) within the recommended range (140–180 mg/dL; 7.78–10 mmol/L), it may be continued without any change. Conversely, if glycaemic values are not satisfactory and glycaemic variability (GV) increases, we can implement this therapy with dipeptidyl peptidase-4 inhibitors (DPP-4Is) or glucagon like peptide-1 receptor agonists (GLP-1 RAs) in patients without signs of or risk factors for heart failure (HF), whereas sodium-glucose co-transporters 2 inhibitors (SGLT-2Is) must be preferred in patients with signs of or risk factors for HF.
Figure 2 Proposal for a multitargeted therapeutic strategy to improve the prognosis in non-diabetic patients with stress-induced hyperglycaemia (SIH) at admission for acute coronary syndrome (ACS). Pharmacological therapy for SIH in non-diabetic ACS patient should start with administration of α1/β1-blockers, ACE inhibitors (ACEi) or angiotensin receptor blockers (ARBs) and n3-polyunsaturated fatty acids (n3-PUFAs) in addition to insulin. If this strategy reaches an efficient glycaemic control (GC) within the recommended range (140–180 mg/dL; 7.78–10 mmol/L), it may be continued without any change. Conversely, if glycaemic values are not satisfactory and glycaemic variability (GV) increases, we can implement this therapy with dipeptidyl peptidase-4 inhibitors (DPP-4Is) or glucagon like peptide-1 receptor agonists (GLP-1 RAs) in patients without signs of or risk factors for heart failure (HF), whereas sodium-glucose co-transporters 2 inhibitors (SGLT-2Is) must be preferred in patients with signs of or risk factors for HF.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 209 references

Research works printed but not linked: 1

  1. Diaz, 1998, Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group, Circulation, 98, 2227

Cited by

See all 71

Metadata

Authors
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C.
Affiliations
  • Ospedale Antonio Cardarelli (IT)
  • University of Naples Federico II (IT)
  • MultiMedica (IT)
Corresponding author
Morisco, Carmine
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-01-14
Volume
22
Issue
2
Pages
775
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3121056265
Cited by
61
References
216
Citations by year
2026: 12 · 2025: 14 · 2024: 14 · 2023: 10 · 2022: 7 · 2021: 4
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
stress hyperglycemia, acute coronary syndrome, non-diabetic patients, insulin therapy, prognosis, adrenergic system, renin-angiotensin system, hyperglucagonaemia, free fatty acids, beta-cell dysfunction, molecular mechanisms, treatment options
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Animals, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Stress, Psychological, Acute Coronary Syndrome, Dipeptidyl-Peptidase IV Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives. https://app.cochat.ai/papers/10.3390/ijms22020775
The paper
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021). Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22020775

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.